The aim of this article is to review potential regenerative treatment strategies for canine IVD degeneration, with specific emphasis on cell-based strategies.
Future exploration of the canine model as a model of IVD-associated spinal pain will further demonstrate its translational capabilities with the added ethical benefit of treating an existing veterinary patient population with IVDD.
Further long-term investigations on specific BCP efficacy in horses with osteoarthritis, preferably in blinded and placebo-controlled studies, should be performed to confirm these first positive results.
These results provide further indication that vitacoxib is safe and well-tolerated in rats after 180 days of daily oral administration at 6 mg/kg bw and the NOAEL for both sexes was 6 mg/kg bw for 180 consecutive days.
Future research focused on key active ingredients would enable consistent and improved efficacy from GSM-based products for the purpose of improved animal health.
